0001520138-25-000352.txt : 20251113 0001520138-25-000352.hdr.sgml : 20251113 20251113170103 ACCESSION NUMBER: 0001520138-25-000352 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20251110 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251113 DATE AS OF CHANGE: 20251113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOVIE INC. CENTRAL INDEX KEY: 0001580149 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 462510769 STATE OF INCORPORATION: NV FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39015 FILM NUMBER: 251479571 BUSINESS ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 BUSINESS PHONE: 775-888-3162 MAIL ADDRESS: STREET 1: 680 W NYE LANE STREET 2: SUITE 201 CITY: CARSON CITY STATE: NV ZIP: 89703 FORMER COMPANY: FORMER CONFORMED NAME: NANOANTIBIOTICS, INC. DATE OF NAME CHANGE: 20130625 8-K 1 bivi-20251113_8k.htm CURRENT REPORT
false 0001580149 0001580149 2025-11-10 2025-11-10 0001580149 bivi:ClassCommonStockParValue0.0001PerShareMember 2025-11-10 2025-11-10 0001580149 bivi:WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember 2025-11-10 2025-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 10, 2025

 

BioVie Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   001-39015   46-2510769
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

680 W Nye Lane Suite 201

Carson City, NV

  89703
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (775) 888-3162

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Class A Common Stock, Par Value $0.0001 Per Share BIVI The Nasdaq Stock Market, LLC
Warrants to purchase Class A Common Stock, $0.0001 par value per share BIVIW The Nasdaq Stock Market, LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.

 

On November 10, 2025, at the 2025 annual meeting of stockholders (the “Annual Meeting”) of BioVie Inc. (the “Company”), the Company’s stockholders approved an amendment and restatement of the BioVie Inc. 2019 Omnibus Equity Incentive Plan (the “2019 Plan”), effective November 10, 2025.

 

The purpose of the 2019 Plan is to help the Company attract, retain and provide incentives to employees, directors, and consultants of the Company and its affiliates, and to align the interests of such service providers with those of the Company’s stockholders. The amended and restated 2019 Plan increases the number of shares of common stock authorized for issuance under the 2019 Plan to 3,100,000 shares, enabling the Company to continue to grant equity compensation under the 2019 Plan.

 

The foregoing description of the amended and restated 2019 Plan is qualified in its entirety by reference to the actual terms of the amended and restated 2019 Plan, a copy of which is attached as Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 25, 2025.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
10.1   BioVie Inc. 2019 Omnibus Equity Incentive Plan (Amended and Restated through November 10, 2025) (incorporated by reference to Appendix A to the Definitive Proxy Statement on Schedule 14A, filed on September 25, 2025)
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BioVie INC.
     
  By:   /s/ Joanne Wendy Kim
    Name:   Joanne Wendy Kim
    Title: Chief Financial Officer
       
Date: November 13, 2025      

 

 

 

EX-101.SCH 2 bivi-20251110.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 bivi-20251110_def.xml XBRL DEFINITION FILE EX-101.LAB 4 bivi-20251110_lab.xml XBRL LABEL FILE Class of Stock [Axis] Class A Common Stock, Par Value $0.0001 Per Share Warrants to purchase Class A Common Stock, $0.0001 par value per share Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 bivi-20251110_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.25.3
Cover
Nov. 10, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 10, 2025
Entity File Number 001-39015
Entity Registrant Name BioVie Inc.
Entity Central Index Key 0001580149
Entity Tax Identification Number 46-2510769
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 680 W Nye Lane Suite 201
Entity Address, City or Town Carson City
Entity Address, State or Province NV
Entity Address, Postal Zip Code 89703
City Area Code 775
Local Phone Number 888-3162
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Class A Common Stock, Par Value $0.0001 Per Share  
Title of 12(b) Security Class A Common Stock, Par Value $0.0001 Per Share
Trading Symbol BIVI
Security Exchange Name NASDAQ
Warrants to purchase Class A Common Stock, $0.0001 par value per share  
Title of 12(b) Security Warrants to purchase Class A Common Stock, $0.0001 par value per share
Trading Symbol BIVIW
Security Exchange Name NASDAQ
XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.3 html 3 22 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioviepharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports bivi-20251110.xsd bivi-20251110_def.xml bivi-20251110_lab.xml bivi-20251110_pre.xml bivi-20251113_8k.htm http://xbrl.sec.gov/dei/2025 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bivi-20251113_8k.htm": { "nsprefix": "bivi", "nsuri": "http://bioviepharma.com/20251110", "dts": { "schema": { "local": [ "bivi-20251110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd", "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd", "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd", "https://xbrl.sec.gov/country/2025/country-2025.xsd", "https://xbrl.sec.gov/dei/2025/dei-2025.xsd", "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd" ] }, "definitionLink": { "local": [ "bivi-20251110_def.xml" ] }, "labelLink": { "local": [ "bivi-20251110_lab.xml" ] }, "presentationLink": { "local": [ "bivi-20251110_pre.xml" ] }, "inline": { "local": [ "bivi-20251113_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2025": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2025": 25 }, "report": { "R1": { "role": "http://bioviepharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2025-11-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20251113_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-11-10", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bivi-20251113_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentDescription", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AmendmentFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AnnualInformationForm", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CityAreaCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "bivi_ClassCommonStockParValue0.0001PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20251110", "localname": "ClassCommonStockParValue0.0001PerShareMember", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class A Common Stock, Par Value $0.0001 Per Share" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "ClassOfStockDomain", "presentation": [ "http://bioviepharma.com/role/Cover" ], "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CountryRegion", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentAnnualReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentTransitionReport", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentType", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressCountry", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFileNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityFilerCategory", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityRegistrantName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityShellCompany", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntitySmallBusiness", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Extension", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "LocalPhoneNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12bTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "Security12gTitle", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityExchangeName", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SecurityReportingObligation", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "SolicitingMaterial", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementLineItems", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2025", "localname": "StatementTable", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "TradingSymbol", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "bivi_WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioviepharma.com/20251110", "localname": "WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase Class A Common Stock, $0.0001 par value per share" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2025", "localname": "WrittenCommunications", "presentation": [ "http://bioviepharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001520138-25-000352-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001520138-25-000352-xbrl.zip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end XML 15 bivi-20251113_8k_htm.xml IDEA: XBRL DOCUMENT 0001580149 2025-11-10 2025-11-10 0001580149 bivi:ClassCommonStockParValue0.0001PerShareMember 2025-11-10 2025-11-10 0001580149 bivi:WarrantsToPurchaseClassCommonStock0.0001ParValuePerShareMember 2025-11-10 2025-11-10 iso4217:USD shares iso4217:USD shares false 0001580149 8-K 2025-11-10 BioVie Inc. NV 001-39015 46-2510769 680 W Nye Lane Suite 201 Carson City NV 89703 775 888-3162 false false false false Class A Common Stock, Par Value $0.0001 Per Share BIVI NASDAQ Warrants to purchase Class A Common Stock, $0.0001 par value per share BIVIW NASDAQ false